Icon PLC (ICLR) delivered earnings and revenue surprises of 3.57% and 0.58%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to ...

ICON plc, a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Leerink Partners Global ...

Icon Plc (NASDAQ: ICLR) is a contract research organization (“CRO”). In the Q3 2024 letter, I highlighted our investment in Medpace (MEDP) another CRO that directly competes with Icon.

Wall Street expects a year-over-year decline in earnings on lower revenues when Icon PLC (ICLR) reports results for the quarter ended March 2025. While this widely-known consensus outlook is ...

Icon PLC (ICLR) came out with quarterly earnings of $3.19 per share, beating the Zacks Consensus Estimate of $3.08 per share. This compares to earnings of $3.47 per share a year ago. These figures ...

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the William ...

With headquarters in Dublin, Ireland, ICON employed approximately 41,100 employees in 106 locations in 53 countries as at December 31, 2023. For further information about ICON, visit: www.iconplc.com.

With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 109 locations in 53 countries as at March 31, 2023. For further information about ICON, visit: www.iconplc.com.

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research organisations (CRO) for phase 1 ...